This fact sheet is for men who would like to know more about bisphosphonates to relieve pain in prostate cancer that has spread to the bones.

Last updated: June 2015
To be reviewed: June 2018 

 

References  

  • Bader P, Echtle D, Fonteyne V, Livadas K, De Meerleer G, Paez Borda A, et al. Guidelines on pain management. European Association of Urology; 2010.
  • British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS). Multi-disciplinary Team (MDT) Guidance for Managing Prostate Cancer. 2013.
  • British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS): Section of Oncology, British Prostate Group (BPG). MDT (Multi-disciplinary Team) Guidance for Managing Prostate Cancer 2nd Edition (November 2009). 2009.
  • Deng X, He G, Liu J, Luo F, Peng X, Tang S, et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treatment Reviews. 2014 Jul;40(6):730–8.
  • Drudge-Coates L, Turner B. Bone micro-environment in prostate cancer: impact, treatment and implications for nursing practice. International Journal of Urological Nursing. 2012 Jul;6(2):83–90.
  • Drudge-Coates L, Turner B. Treatment-related osteonecrosis of the jaw: presentation and management. cancer nursing practice. 2012;11(5):28–36.
  • electronic Medicines Compendium. Zometa 4mg/5ml Concentrate for Solution for Infusion [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/EMC/medicine/14062/SPC/Zometa+4mg+5ml+Concentrate+for+Solution+for+Infusion/
  • electronic Medicines Compendium. Zometa 4mg/100ml Solution for Infusion [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/EMC/medicine/25058/SPC/Zometa+4mg+100ml+Solution+for+Infusion/
  • Electronic Medicines Compendium. Zometa 4mg/100ml Solution for Infusion - Patient Information Leaflet (PIL) [Internet]. [cited 2015 Feb 24]. Available from: http://www.medicines.org.uk/emc/medicine/25059/PIL/Zometa+4mg+100ml+Solution+for+Infusion
  • Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P, et al. Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals. Oral Oncology. 2013 Sep;49(9):878–86.
  • Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Annals of Oncology. 2011 Apr 1;22(4):761–72.
  • Healthcare Improvement Scotland. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE (Multiple) Technology Appraisal Guidance No 265 [Internet]. [cited 2015 May 13]. Available from: http://www.healthcareimprovementscotland.org/programmes/nice_guidance_and_scotland/mta_resources/appraisal_265.aspx?iru=FV15K62K54
  • Jacobs C, Ng T, Ong M, Clemons M. Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. Current Opinion in Supportive and Palliative Care. 2014 Dec;8(4):420–8.
  • Lee S-H, Chan R-C, Chang S-S, Tan Y-L, Chang K-H, Lee MC, et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Supportive Care in Cancer. 2014 Feb;22(2):553–60.
  • MHRA. Drug Safety Update. 2009.
  • Morgans AK, Smith MR. Bone-Targeted Agents. Urologic Clinics of North America. 2012 Nov;39(4):533–46.
  • Mundy GR, Roodman GD, Smith MR. New Opportunities for the Management of Cancer-Related Bone Complications. 2009 [cited 2013 Nov 4]; Available from: http://www.curatio-cme.com/newsletters/CAHO_New_Opp_May2009.pdf
  • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
  • NICE. CG58 Prostate cancer: NICE guidance [Internet]. [cited 2013 Jan 9]. Available from: http://publications.nice.org.uk/prostate-cancer-cg58
  • Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer [Internet]. 2014 Dec 23 [cited 2015 Feb 18]; Available from: http://link.springer.com/10.1007/s00520-014-2525-4
  • Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews Rheumatology. 2012 Feb;8:90–6.
  • Scottish Medicines Consortium. Zoledronic acid (Zometa®) [Internet]. [cited 2015 May 13]. Available from: https://www.scottishmedicines.org.uk/SMC_Advice/Advice/Zoledronic_acid__Zometa__-_Independent_Review/Zoledronic_acid__Zometa___IPR
  • Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology [Internet]. 2011 May 10 [cited 2013 Dec 11]; Available from: http://www.nature.com/doifinder/10.1038/nrclinonc.2011.67
  • Yuen KK, Shelley M, Sze WM, Wilt TJ, Mason M. Bisphosphonates for advanced prostate cancer (Review). Cochrane Database of Systematic Reviews. 2006;(4).

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication